XFOR · Insider Trading
X4 Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by XFOR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Adam R Craig | Executive Chairman | Buy | +4,600 | +$11.88K |
| 2026-10-05 | David Kirske | Chief Financial Officer | Sell | −11,767 | −$33.66K |
| 2026-08-13 | John Volpone | President | Sell | −24,576 | −$109.23K |
| 2026-08-13 | Adam R Craig | Executive Chairman | Sell | −47,436 | −$210.83K |
| 2026-07-01 | Kelly Gold | Director | A | +110,000 deriv. | — |
| 2026-07-01 | David Kirske | Chief Financial Officer | Sell | −8,543 | −$36.43K |
| 2026-05-13 | David Kirske | Chief Financial Officer | Sell | −16,961 | −$72.82K |
| 2026-01-07 | Gary Bridger | Director | A | +110,000 deriv. | — |
| 2026-01-05 | Murray Stewart | Director | A | +110,000 deriv. | — |
| 2026-01-05 | Francoise de Craecker | Director | A | +110,000 deriv. | — |
| 2026-01-05 | Michael S Wyzga | Director | A | +110,000 deriv. | — |
| 2025-10-31 | David Kirske | Chief Financial Officer | A | +1,552,769 deriv. | — |
| 2025-10-31 | Adam R Craig | Executive Chairman | A | +2,329,154 deriv. | — |
| 2025-10-31 | John Volpone | President | A | +2,329,154 deriv. | — |
| 2025-10-27 | Adam R Craig | Executive Chairman | Buy | +86,206 | +$250.00K |
| 2025-08-14 | David Kirske | Chief Financial Officer | A | +193,254 | — |
| 2025-08-14 | Adam R Craig | Executive Chairman | A | +289,881 | — |
| 2025-08-14 | John Volpone | President | A | +289,881 | — |
| 2025-07-03 | Natasha Fay Thoren | Chief Legal Officer | A | +3,333 | — |
| 2025-06-10 | Keith Woods | Director | A | +1,500 | — |
| 2025-06-10 | Francoise de Craecker | Director | A | +1,500 | — |
| 2025-06-10 | Michael S Wyzga | Director | A | +1,500 | — |
| 2025-06-10 | David W J McGirr | Director | A | +1,500 | — |
| 2025-06-10 | Gary Bridger | Director | A | +1,500 | — |
| 2025-06-10 | Murray Stewart | Director | A | +1,500 | — |
| 2025-06-03 | Mark Baldry | Chief Commercial Officer | A | +1,032 | +$2.56K |
| 2025-05-20 | Mark Baldry | Chief Commercial Officer | Buy | +1,032 | +$2.56K |
| 2025-02-14 | Christophe Arbet-Engels | Chief Medical Officer | A | +850,000 | — |
| 2025-02-14 | Adam S. Mostafa | Chief Financial Officer | A | +850,000 | — |
| 2025-02-14 | Paula Ragan | President and CEO | A | +2,250,000 | — |
| 2025-02-14 | Mary DiBiase | Chief Operating Officer | A | +650,000 | — |
| 2025-02-14 | Mark Baldry | Chief Commercial Officer | MIXED | +635,050 | +$19.25K |
| 2025-01-27 | Mark Baldry | Chief Commercial Officer | MIXED | +45,614 | −$13.24K |
| 2025-01-27 | Mary DiBiase | Chief Operating Officer | MIXED | +38,920 | −$10.09K |
| 2025-01-27 | Paula Ragan | President and CEO | MIXED | +93,467 | −$34.72K |
| 2025-01-27 | Adam S. Mostafa | Chief Financial Officer | MIXED | — | −$33.95K |
| 2025-01-27 | Christophe Arbet-Engels | Chief Medical Officer | MIXED | +14,207 | −$5.28K |
| 2024-11-19 | Paula Ragan | President and CEO | Sell | −31,897 | −$12.58K |
| 2024-10-16 | Paula Ragan | President and CEO | Sell | −31,897 | −$17.93K |
| 2024-10-08 | Paula Ragan | President and CEO | MIXED | +292,645 | −$131.52K |
| 2024-10-08 | Mary DiBiase | Chief Operating Officer | MIXED | +162,950 | −$38.33K |
| 2024-10-08 | Arthur Taveras | Chief Scientific Officer | MIXED | +153,725 | −$43.31K |
| 2024-10-08 | Mark Baldry | Chief Commercial Officer | MIXED | +23,819 | −$6.51K |
| 2024-10-08 | Adam S. Mostafa | Chief Financial Officer | MIXED | — | −$126.90K |
| 2024-09-11 | Mary DiBiase | Chief Operating Officer | Sell | −2,642 | −$1.74K |
| 2024-06-11 | Keith Woods | Director | A | +45,000 | — |
| 2024-06-11 | Gary Bridger | Director | A | +45,000 | — |
| 2024-06-11 | William Aliski | Director | A | +45,000 | — |
| 2024-06-11 | Alison Frances Lawton | Director | A | +45,000 | — |
| 2024-06-11 | Murray Stewart | Director | A | +45,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Adam R Craig | Executive Chairman | 333,251 | $1.08M |
| John Volpone | President | 265,305 | $862.24K |
| David Kirske | Chief Financial Officer | 155,983 | $506.94K |
| Paula Ragan | President and CEO | 111,246 | $361.55K |
| Mary DiBiase | Chief Operating Officer | 38,033 | $123.61K |
| Christophe Arbet-Engels | Chief Medical Officer | 28,807 | $93.62K |
| Adam S. Mostafa | Chief Financial Officer | 28,333 | $92.08K |
| Mark Baldry | Chief Commercial Officer | 25,337 | $82.35K |
| Natasha Fay Thoren | Chief Legal Officer | 9,462 | $30.75K |
| Murray Stewart | Interim Chief Medical Officer | 7,883 | $25.62K |
| Keith Woods | Director | 6,000 | $19.50K |
| Michael S Wyzga | Director | 5,555 | $18.05K |
| David W J McGirr | Director | 4,722 | $15.35K |
| Gary Bridger | Director | 4,722 | $15.35K |
| Francoise de Craecker | Director | 4,722 | $15.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XFOR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.